Work disability Clause Samples
Work disability. During the first year of sickness in which the Sickness Benefits Act is applicable, and the two consecutive years thereafter in which there is a situation of work disability as defined in WAO/AAW [Disablement Insurance Act/General Work Disability Act], the Company shall supplement the benefits under the Sickness Benefits Act and/or WAO/AAW (or any legal regulation which replaces them or which is created in addition to them) up to 100% of the salary in effect on the day preceding the first day of illness, adjusted in the manner as described in section (d) of this clause. After this period of time the Director shall receive a work disability benefit in accordance with the terms set forth in the work disability policy and in compliance with the terms stipulated therein, which may be amended from time to time, which also applies for employees to which the Collective Labor Agreement Coffee & Tea of Koninklijke ▇▇▇▇▇ ▇▇▇▇▇▇▇ B.V. is applicable. Benefit payments from the abovementioned insurances shall, in the event of retirement of the Director during the period of sickness or work disability, be deducted by the pension payments for the period in question.
Work disability. Approximately half of RA patients in the UK are of working age at the onset of symptoms. [▇▇▇▇▇▇▇ et al. 1994] A study from the US suggests that the greatest risk of work disability seems to occur within the first three years following the onset of symptoms. [Sokka 2003] One longitudinal study of patients with early RA in the UK has shown that just over a fifth of patients who were in employment at the onset of symptoms of RA stopped working after 5 years of disease onset because of their RA. [▇▇▇▇▇ et al. 2002] A study from Canada showed that about a third of RA patients from their cohort of 239 patients left employment early, although this was influenced by socioeconomic factors. [▇▇▇▇▇▇▇ et al. 2004] Work related disability is particularly common for RA, with around 9.4 million working days lost in the UK due to RA in 1999-2000, equivalent to £833 million in lost production. [ARMA standards of care for people with inflammatory arthritis 2004] This is clearly a significant sum of money, especially considering the current economic situation. In recent years there has been more focus on the cost of RA work disability, predominantly spearheaded by the drug companies responsible for the development of biologic therapies who are understandably eager to show that their treatments are cost beneficial given their relatively higher costs compared to traditional DMARDs. The ASPIRE study which compared methotrexate monotherapy with methotrexate, infliximab combination therapy showed a significant reduction in unemployment at 1 year in those on combination therapy compared to monotherapy (14% unemployed vs. 8% unemployed). The study also showed that those patients receiving combination therapy had a significantly higher likelihood of employability (Odds ration 2.4). Significantly fewer employed patients receiving combination therapy reported lost working days than those on monotherapy and 79% vs. 67% of patient on monotherapy reported no lost working days during 1 year of treatment. [▇▇▇▇▇▇ et al 2006]
Work disability. 1. a. In the case of work disability, the employee shall retain 85% of the fixed agreed wage and the accompanying leave/holiday allowance during the first and second years of sickness, with due observance of the provisions of Article 17, paragraph 3 of this CLA. If the amount that would be paid out to the employee on the grounds of the foregoing is lower than the amount the employee is entitled to on the grounds of Book 7, Article 629 of the DCC, then payment must proceed according to the latter amount.